Synthesis and SAR of novel Re/99mTc-Labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia

Journal of Medicinal Chemistry

Volumn 56, Issue 2, 2013, Pages 510-520

  Lu, Genliang ^a   Hillier, Shawn M ^a   Maresca, Kevin P ^a   Zimmerman, Craig N ^a   Eckelman, William C ^a   Joyal, John L ^a   Babich, John W ^a  

^a Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(PYRIDIN 2 YLMETHYL)(4 SULFAMOYLPHENETHYL)AMINO]ACETIC ACID RHENIUM TRICARBONYL COMPLEX TC 99M; 2,2' [2 [2 [[[[1 (CARBOXYMETHYL) 1H IMIDAZOL 2 YL]METHYL](4 SULFAMOYLPHENETHYL]AMINO]METHYL] 1H IMIDAZOL 1 YL]ACETYLAZANEDIYL]DIACETIC ACID RHENIUM TRICARBONYL COMPLEX TC 99M; 2,2' [2,2' (4 SULFAMOYLBENZYLAZANEDIYL)BIS(METHYLENE)BIS(1H IMIDAZOLE 2,1 DIYL)]DIACETIC ACID RHENIUM TRICARBONYL COMPLEX TC 99M; 2,2' [2,2' (4 SULFAMOYLPHENETHYLAZANEDIYL)BIS(METHYLENE)BIS(1H IMIDAZOLE 2,1 DIYL ACETYLAZANEDIYL)]DIACETIC ACID RHENIUM TRICARBONYL COMPLEX TC 99M; 2,2' [2,2' (4 SULFAMOYLPHENETHYLAZANEDIYL)BIS(METHYLENE)BIS(1H IMIDAZOLE 2,1 DIYL)]DIACETIC ACID RHENIUM TRICARBONYL COMPLEX TC 99M; 2,2',2'',2''' [[2,2' (2,2' [[(4 SULFAMOYLBENZYL)AZANEDIYL]BIS(METHYLENE)]BIS(1H IMIDAZOLE 2,1 DIYL)]BIS(ACETYL)]BIS(AZANETRIYL)]TETRAACETIC ACID RHENIUM TRICARBONYL COMPLEX TC 99M; 2,2',2'',2''' [[2,2' [2,2' [[(4 SULFAMOYLPHENETHYL)AZANEDIYL]BIS(METHYLENE)]BIS(1H IMIDAZOLE 2,1 DIYL)]BIS(ACETYL)]BIS(AZANETRIYL)]TETRAACETIC ACID TC 99M; 2,2',2'',2''' [[2,2' [2,2' [[[4 (4 SULFAMOYLPHENOXY)BUTYL]AZANEDIYL]BIS(METHYLENE)]BIS(1H IMIDAZOLE 2,1 DIYL)]BIS(ACETYL)]BIS(AZANETRIYL)]TETRAACETIC ACID RHENIUM TRICARBONYL COMPLEX TC 99M; 2,2',2''2''' [[2,2' [2,2' [[[4 (4 SULFAMOYLPHENOXY)BUTYL]AZANEDIYL]BIS(METHYLENE)]BIS(1H IMIDAZOLE 2,1 DIYL)]BIS(ACETYL)]BIS(AZANETRIYL)]TETRAACETIC ACID RHENIUM TRICARBONYL COMPLEX TC 99M; 4 [2 [2 [[[[1 [2 [BIS(CARBOXYMETHYL)AMINO] 2 OXOETHYL] 1H IMIDAZOL 2 YL]METHYL](4 SULFAMOYLPHENETHYL)AMINO]METHYL] 1H IMIDAZOL 1 YL]ACETAMIDO] 4 (2 CARBOXYETHYL)HEPTANEDIOIC ACID RHENIUM TC 99M; 4 [2 [2 [[[[1 [2 [BIS(CARBOXYMETHYL)AMINO] 2 OXOETHYL] 1H IMIDAZOL 2 YL]METHYL](4 SULFAMOYLPHENETHYL)AMINO]METHYL] 1H IMIDAZOL 1 YL]ACETAMIDO] 4 (2 CARBOXYETHYL)HEPTANEDIOIC ACID TC 99M; 4 [2 [BIS(PYRIDIN 2 YLMETHYL)AMINO]ETHYL]BENZENESULFONAMIDE RHENIUM TRICARBONYL COMPLEX TC 99M; 4 [2 [BIS[(1 METHYL 1H IMIDAZOL 2 YL)METHYL]AMINO]ETHYL]BENZENESULFONAMIDERHENIUM TRICARBONYL COMPLEX TC 99M; 4,4' [[2,2' (2,2' [[[6 (4 SULFAMOYLPHENOXY)HEXYL]AZANEDIYL]BIS(METHYLENE)]BIS(1H IMIDAZOLE 2,1 DIYL)]BIS(ACETYL)]BIS(AZANEDIYL)]BIS[4 (2 CARBOXYETHYL)HEPTANEDIOIC ACID] RHENIUM TRICARBONYL COMPLEX TC 99M; 4,4' [[2,2' [2,2' [[(4 SULFAMOYLPHENETHYL)AZANEDIYL]BIS(METHYLENE)]BIS(1H IMIDAZOLE 2,1 DIYL)]BIS(ACETYL)]BIS(AZANEDIYL)]BIS[4 (2 CARBOXYETHYL)HEPTANEDIOIC ACID] TC 99M; 4,4' [[2,2' [2,2' [[(4-SULFAMOYLPHENETHYL)AZANEDIYL]BIS(METHYLENE)]BIS(1H IMIDAZOLE 2,1 DIYL)]BIS(ACETYL)]BIS(AZANEDIYL)]BIS[4 (2 CARBOXYETHYL)]HEPTANEDIOIC ACID RHENIUM TRICARBONYL COMPLEX TC 99M; 4,4' [[2,2' [2,2' [[[4 (4 SULFAMOYLPHENOXY)BUTYL]AZANEDIYL]BIS(METHYLENE)]BIS(1H IMIDAZOLE 2,1 DIYL)]BIS(ACETYL)]BIS(AZANEDIYL)]BIS[4 (2 CARBOXYETHYL)HEPTANEDIOIC ACID] RHENIUM TRICARBONYL COMPLEX TC 99M; 4,4' [[2,2' [2,2' [[[4 (4 SULFAMOYLPHENOXY)BUTYL]AZANEDIYL]BIS(METHYLENE)]BIS(1H IMIDAZOLE 2,1 DIYL)]BIS(ACETYL)]BIS(AZANEDIYL)]BIS[4 (2 CARBOXYETHYL)HEPTANEDIOIC ACID] TC 99M; BENZENESULFONAMIDE DERIVATIVE; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG PURITY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYPOXIA; IC 50; IN VITRO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; TUMOR HYPOXIA;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; RADIOISOTOPES; RHENIUM; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84872799450     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3015348     Document Type: Article

References (37)

1. Thiry, A.; Dogné, J. M.; Masereel, B.; Supuran, C. T. Targeting tumor-associated carbonic anhydrase IX in cancer therapy Trends Pharmacol. Sci. 2006, 27, 566-573
2. Scozzafava, A.; Supuran, C. T. Carbonic Anhydrase Inhibitors Curr. Med. Chem.: Immunol. Endocr. Metab. Agents 2001, 1, 61-97
3. Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors Med. Res. Rev. 2003, 23, 146-189
4. Pastoreková, S.; Parkkila, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects J. Enzyme Inhib. Med. Chem. 2004, 19, 199-229
5. Wykoff, C. C.; Beasley, N. J.; Watson, P. H.; Turner, K. J.; Pastorek, J.; Sibtain, A.; Wilson, G. D.; Turley, H.; Talks, K. L.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J.; Harris, A. L. Hypoxia-inducible expression of tumor-associated carbonic anhydrases Cancer Res. 2000, 60, 7075-7083
6. 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma Int. J. Cancer 2003, 105, 873-881
7. Chia, S. K.; Wykoff, C. C.; Watson, P. H.; Han, C.; Leek, R. D.; Pastorek, J.; Gatter, K. C.; Ratcliffe, P.; Harris, A. L. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma J. Clin. Oncol. 2001, 19, 3660-3668
8. Divgi, C. R.; Pandit-Tasker, N.; Jungbluth, A. A.; Reuter, V. E.; Gonen, M.; Ruan, S.; Pierre, C.; Nagel, A.; Pryma, D. A.; Humm, J.; Larson, S. M.; Old, L. J.; Russo, P. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial Lancet Oncol. 2007, 8, 304-310
9. Le, Q. T.; Chen, E.; Salim, A.; Cao, H.; Kong, C. S.; Whyte, R.; Donington, J.; Cannon, W.; Wakelee, H.; Tibshirani, R.; Mitchell, J. D.; Richardson, D.; O'Byrne, K. J.; Koong, A. C.; Giaccia, A. J. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers Clin. Cancer Res. 2006, 12, 1507-1514
10. Chrastina, A.; Pastorekova, A.; Pastorek, J. Immunotargeting of human cervical carcinoma xenograft expressing CAIX tumor-associated antigen by 125I-labeled M75 monoclonal antibody Neoplasma 2003, 50, 13-21
11. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model J. Nucl. Med. 1999, 4, 177-183
12. Friedrich, S. W.; Lin, S. C.; Stoll, B. R.; Baxter, L. T.; Munn, L. L.; Jain, R. K. Antibody-Directed Effector Cell Therapy of Tumors: Analysis and Optimization Using a Physiologically Based Pharmacokinetic Model Neoplasia 2002, 4, 449-463
13. Maresca, K. P.; Hillier, S. M.; Femia, F. J.; Keith, D.; Barone, C.; Joyal, J. L.; Zimmerman, C. N.; Kozikowski, A. P.; Barrett, J. A.; Eckelman, W. C.; Babich, J. W. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer J. Med. Chem. 2009, 52, 347-357
14. Hillier, S. M.; Maresca, K. P.; Femia, F. J.; Marquis, J. C.; Foss, C. A.; Nguyen, N.; Zimmerman, C. N.; Barrett, J. A.; Eckelman, W. C.; Pomper, M. G.; Joyal, J. L.; Babich, J. W. Preclinical evaluation of novel glutamate-urea-lysine analogs that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer Cancer Res. 2009, 69, 6932-6940
15. Vullo, D.; Scozzafava, A.; Pastorekova, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrous inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered Bioorg. Med. Chem. Lett. 2004, 14, 2351-2356
16. Smaine, F.-Z.; Winum, J.-Y.; Montero, J.-L.; Regainia, Z.; Vullo, D.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides Bioorg. Med. Chem. Lett. 2007, 17, 5096-5100
17. Thirty, A.; Ledecq, M.; Cecchi, A.; Dogne, J.-M.; Wouters, J.; Supuran, C. T.; Masereel, B. Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-assocaited isozyme CA IX J. Med. Chem. 2006, 49, 2743-2749
18. Casey, J. R.; Morgan, P. E.; Vullo, D.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX J. Med. Chem. 2004, 47, 2337-2347
19. Stiti, M.; Cecchi, A.; Rami, M.; Abdaui, M.; Barragan-Montero, V.; Scozzafava, A.; Guari, Y.; Winum, J.-Y.; Supuran, C. T. Carbonic anhydrous inhibitor coated gold nanoparticles selectivity inhibit the tumor-assocaited isoform IX over the cytosolic isozymes I and II J. Am. Chem. Soc. 2008, 130, 16130-16131
20. Temperini, C.; Innocenti, A.; Scozzafava, A.; Parkkila, S.; Supuran, C. T. The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydraseinhibitors J. Med. Chem. 2010, 53, 850-854
21. Morris, J. C.; Chiche, J.; Grellier, C.; Lopez, M.; Bornaghi, L. F.; Maresca, A.; Supuran, C. T.; Pouysségur, J.; Poulsen, S.-A. Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors J. Med. Chem. 2011, 54, 6905-6918
22. Alterio, V.; Fiore, A. D.; D'Ambrosio, K.; Supuran, C. T. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem. Rev. 2012, 112, 4421-4468
23. Cecchi, A.; Hulikova, A.; Pastorek, J.; Pastorekova, S.; Scozzafava, A.; Winum, J. Y.; Montero, J. L.; Supuran, C. T. J. Med. Chem. 2005, 46, 4834-4841
24. Dubois, L.; Douma, K.; Supuran, C. T.; Chiu, R. K; van Zandvoort, M. A.; Pastorekova, S.; Scozzafava, A.; Wouters, B. G.; Lambin, P. Radiother. Oncol. 2007, 83, 367-373
25. Alterio, V.; Vitale, R. M.; Monti, S. M.; Pedone, C.; Scozzafava, A.; Cecchi, A.; De Simone, G.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX J. Am. Chem. Soc. 2006, 128, 8329-8335
26. Kolb, H. C.; Walsh, J. C.; Kasi, D.; Mocharla, V.; Wang, B.; Gangadharmath, U. B.; Duclos, B. A.; Chen, K.; Zhang, W.; Chen, G.; Padgett, H. C.; Karimi, F.; Scott, P. J.; Gao, Z.; Liang, Q.; Collier, T. L.; Zhao, T.; Xia, C. Develepment of triazole derivatives as molecular imaging probes for carbonic anhydrase-IX using click chemistry. PCT Int. Appl. WO 2008/124703 A2, 2008.
27. Mariani, G.; Nicolini, M.; Wagner, H. W. Technetium in Chemistry and Nuclear Medicine; Cortina International: Verona, 1983; Vol. 1, p 131.
28. Bartholomae, M.; Valliant, J.; Maresca, K. P.; Babich, J. W.; Zubieta, J. Single amino acid chelates: a strategy for the design of technetium and rhenium radiopharmaceuticals Chem. Commun. 2009, 493-512
29. Jurisson, S. S.; Lyden, J. D. Potential technetium small molecule radiopharmaceuticals Chem. Rev. 1999, 99, 2205
30. Heeg, M. J.; Jurisson, S. The role of inorganic chemistry in the development of radiometal agents for cancer therapy Acc. Chem. Res. 1999, 32 (12) 1053-1060
31. Nicolini, M.; Bandoli, G.; Mazzi, U., Eds. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine; S G Eitorial Publishers: New York, 2006; Vol. 7.
32. Lu, G.; Maresca, K. P.; Hillier, S. P.; Zimmerman, C. N.; Eckelman, W. C.; Joyal, J. L.; Babich, J. W. Synthesis and SAR of 99m-Tc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorg. Med. Chem. Lett. http://dx.doi.org/10.1016/j.bmcl.2012.09.014.
33. Maresca, K. P.; Hillier, S. P.; Lu, G.; Marquis, J. C.; Zimmerman, C. N.; Eckelman, W. C.; Joyal, J. L.; Babich, J. W. Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: Effects of chelate design on pharmacokinetics Inorg. Chim. Acta 2012, 389, 168-175
34. Maresca, K. P.; Marquis, J. C.; Hillier, S. M.; Lu, G.; Femia, F. J.; Zimmerman, C. N.; Eckelman, W. C.; Joyal, J. L.; Babich, J. W. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide Bioconjugate Chem. 2010, 21, 1032-1042
35. Maresca, K. P.; Kronauge, J. F.; Babich, J. W.; Zubieta, J. Direct reductive alkylation of amino acids: Synthesis of bifunctional chelates for nuclear imaging Synthesis 2004, 11, 1759-1766
36. + (M = Re, Tc) directed towards radiopharmaceutical application Coord. Chem. Rev. 1999, 190-192, 901-919
37. Yao, Z.; Bhaumik, J.; Dhanalekshmi, S.; Ptaszek, M.; Rodriguez, P. A.; Lindsey, J. S. Tetrahedron 2007, 63, 10657-10670